Header Logo

Connection

ANITA DESWAL to Female

Back to Details
This is a "connection" page, showing publications ANITA DESWAL has written about Female.
ANITA DESWAL
Connection Strength
0.824
Female
  1. Safety of Contemporary Radiation Therapy in Patients With Cardiac Implantable Electronic Devices: Implications for Clinical Practice. J Am Heart Assoc. 2025 Sep 02; 14(17):e042937.
    View in: PubMed
    Score: 0.035
  2. Regional Variations in Heart Failure Quality and Outcomes: Get With The Guidelines-Heart Failure Registry. J Am Heart Assoc. 2021 04 06; 10(7):e018696.
    View in: PubMed
    Score: 0.026
  3. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int J Obes (Lond). 2020 07; 44(7):1561-1567.
    View in: PubMed
    Score: 0.024
  4. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study. Int J Cardiol. 2017 Apr 15; 233:61-66.
    View in: PubMed
    Score: 0.019
  5. Myocardial Injury, Obesity, and the Obesity Paradox: The ARIC Study. JACC Heart Fail. 2017 01; 5(1):56-63.
    View in: PubMed
    Score: 0.019
  6. ACP Journal Club. Review: In HF with reduced EF, nurse-led titration of HF drugs reduces hospitalizations and mortality. Ann Intern Med. 2016 Apr 19; 164(8):JC41.
    View in: PubMed
    Score: 0.018
  7. Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol. 2014 Dec 30; 64(25):2743-9.
    View in: PubMed
    Score: 0.017
  8. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction. J Card Fail. 2014 Aug; 20(8):560-8.
    View in: PubMed
    Score: 0.016
  9. Prognostic significance of hyponatremia among ambulatory patients with heart failure and preserved and reduced ejection fractions. Am J Cardiol. 2014 Jun 01; 113(11):1834-8.
    View in: PubMed
    Score: 0.016
  10. Incident cancer in patients with heart failure: causation or mere association? J Am Coll Cardiol. 2013 Sep 03; 62(10):887-8.
    View in: PubMed
    Score: 0.015
  11. Lack of definitive evidence for the use of renin-angiotensin system antagonists for heart failure with preserved ejection fraction. Evid Based Med. 2013 Dec; 18(6):226-7.
    View in: PubMed
    Score: 0.015
  12. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012 Mar 13; 59(11):998-1005.
    View in: PubMed
    Score: 0.014
  13. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011 Aug; 17(8):634-42.
    View in: PubMed
    Score: 0.013
  14. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011 Jan; 4(1):53-8.
    View in: PubMed
    Score: 0.013
  15. Predicting quality of life in veterans with heart failure: the role of disease severity, depression, and comorbid anxiety. Behav Med. 2010 Apr-Jun; 36(2):70-6.
    View in: PubMed
    Score: 0.012
  16. Mortality after hospitalization for heart failure in blacks compared to whites. Am J Cardiol. 2010 Mar 01; 105(5):694-700.
    View in: PubMed
    Score: 0.012
  17. Depression and anxiety in ambulatory patients with heart failure. Psychosomatics. 2009 Nov-Dec; 50(6):592-8.
    View in: PubMed
    Score: 0.012
  18. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol. 2009 Jul 28; 54(5):422-8.
    View in: PubMed
    Score: 0.012
  19. The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol. 2007 Jul 03; 50(1):32-6.
    View in: PubMed
    Score: 0.010
  20. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther. 2007 Apr 15; 25(8):913-24.
    View in: PubMed
    Score: 0.010
  21. Translation of clinical trial results into practice: temporal patterns of beta-blocker utilization for heart failure at hospital discharge and during ambulatory follow-up. Am Heart J. 2007 Apr; 153(4):515-22.
    View in: PubMed
    Score: 0.010
  22. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J. 2006 Aug; 152(2):348-54.
    View in: PubMed
    Score: 0.009
  23. Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detection. Circ Cardiovasc Imaging. 2026 Jun; 19(6):e019610.
    View in: PubMed
    Score: 0.009
  24. Early anthracycline cardiotoxicity in adolescents and young adults with sarcoma: a prospective echocardiographic study. ESC Heart Fail. 2026 May 05; 13(3).
    View in: PubMed
    Score: 0.009
  25. Novel risk score for predicting acute cardiovascular and cerebrovascular events after chest radiotherapy in patients with breast or lung cancer. Eur J Prev Cardiol. 2026 Mar 13; 33(4):513-525.
    View in: PubMed
    Score: 0.009
  26. Comparison of morbidity in women versus men with heart failure and preserved ejection fraction. Am J Cardiol. 2006 Apr 15; 97(8):1228-31.
    View in: PubMed
    Score: 0.009
  27. In HFrEF, adding digitoxin to standard care reduced a composite of death or first worsening HF hospitalization at a median 36 mo. Ann Intern Med. 2026 Jan; 179(1):JC8.
    View in: PubMed
    Score: 0.009
  28. Bayesian Learning to Reduce Cardiac Risk of Patients With Locally Advanced Non-Small Cell Lung Cancer Based on Personalized Radiation Therapy Prescription. Int J Radiat Oncol Biol Phys. 2026 Jul 01; 125(3):949-958.
    View in: PubMed
    Score: 0.009
  29. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J. 2005 Dec; 150(6):1233-9.
    View in: PubMed
    Score: 0.009
  30. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool. Eur Heart J. 2025 10 22; 46(40):4090-4101.
    View in: PubMed
    Score: 0.009
  31. Radiation Doses to Cardiac Substructures Predict Elevation in High-sensitivity Cardiac Troponin T Levels in Radiation Therapy for Lung Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar 15; 124(4):1124-1136.
    View in: PubMed
    Score: 0.009
  32. Cardiovascular Outcomes in Patients With Cancer Undergoing Cardiac Implantable Electronic Device Implantation. Pacing Clin Electrophysiol. 2025 11; 48(11):1309-1319.
    View in: PubMed
    Score: 0.009
  33. Long-term results of coronary artery bypass grafting in patients with ischemic cardiomyopathy: the impact of renal insufficiency and noncardiac vascular disease. J Card Fail. 2005 Apr; 11(3):206-12.
    View in: PubMed
    Score: 0.009
  34. Role and optimal dosing of angiotensin-converting enzyme inhibitor therapy. Heart Fail Clin. 2005 Apr; 1(1):25-37.
    View in: PubMed
    Score: 0.008
  35. GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction. J Card Fail. 2025 07; 31(7):989-1001.
    View in: PubMed
    Score: 0.008
  36. Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction. Am J Cardiol. 2004 Oct 15; 94(8):1003-7.
    View in: PubMed
    Score: 0.008
  37. Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 08 01; 12(8):964-987.
    View in: PubMed
    Score: 0.008
  38. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. Eur Heart J Cardiovasc Imaging. 2024 05 31; 25(6):754-761.
    View in: PubMed
    Score: 0.008
  39. Trends of Cardiovascular Disease-Related Mortality in Breast Cancer in the United States From 1999 to 2019. Am J Cardiol. 2024 06 15; 221:110-112.
    View in: PubMed
    Score: 0.008
  40. Impact of race on health care utilization and outcomes in veterans with congestive heart failure. J Am Coll Cardiol. 2004 Mar 03; 43(5):778-84.
    View in: PubMed
    Score: 0.008
  41. Evaluation of Midodrine Utilization in Patients with Cancer and Heart Failure. Cardiovasc Drugs Ther. 2025 06; 39(3):553-562.
    View in: PubMed
    Score: 0.008
  42. SGLT2 Inhibitor Use and Risk of Clinical?Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2024 01; 12(1):67-78.
    View in: PubMed
    Score: 0.008
  43. Global Cardio Oncology Registry (G-COR): Registry Design, Primary Objectives, and Future Perspectives of a Multicenter Global Initiative. Circ Cardiovasc Qual Outcomes. 2023 10; 16(10):e009905.
    View in: PubMed
    Score: 0.008
  44. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Thorac Cardiovasc Surg. 2023 Nov; 166(5):e182-e331.
    View in: PubMed
    Score: 0.008
  45. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. Arch Cardiovasc Dis. 2022 May; 115(5):315-330.
    View in: PubMed
    Score: 0.007
  46. Asymptomatic left ventricular dysfunction: an overlooked part of the continuum of heart failure. Heart Fail Monit. 2002; 3(2):42-8.
    View in: PubMed
    Score: 0.007
  47. Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
    View in: PubMed
    Score: 0.007
  48. Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. Circulation. 2021 11 02; 144(18):1521-1523.
    View in: PubMed
    Score: 0.007
  49. Effects of vesnarinone on peripheral circulating levels of cytokines and cytokine receptors in patients with heart failure: a report from the Vesnarinone Trial. Chest. 2001 Aug; 120(2):453-9.
    View in: PubMed
    Score: 0.007
  50. Geographical Differences in Cardiovascular Comorbidities and Outcomes of COVID-19 Hospitalized Patients in the USA. Cardiology. 2021; 146(4):481-488.
    View in: PubMed
    Score: 0.006
  51. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001 Apr 24; 103(16):2055-9.
    View in: PubMed
    Score: 0.006
  52. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis Rheumatol. 2021 05; 73(5):866-874.
    View in: PubMed
    Score: 0.006
  53. Association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The ARIC Study. J Am Coll Cardiol. 2021 02 09; 77(5):559-571.
    View in: PubMed
    Score: 0.006
  54. Predictors of Mortality by Sex and Race in Heart Failure With Preserved Ejection Fraction: ARIC Community Surveillance Study. J Am Heart Assoc. 2020 10 20; 9(19):e014669.
    View in: PubMed
    Score: 0.006
  55. Home Health Care Use and Post-Discharge Outcomes After Heart?Failure Hospitalizations. JACC Heart Fail. 2020 12; 8(12):1038-1049.
    View in: PubMed
    Score: 0.006
  56. Continuous Wearable Monitoring Analytics Predict Heart Failure Hospitalization: The LINK-HF Multicenter Study. Circ Heart Fail. 2020 03; 13(3):e006513.
    View in: PubMed
    Score: 0.006
  57. Readmissions after Acute Kidney Injury during Left Ventricular Assist Device Implantation Hospitalization. Am J Nephrol. 2020; 51(3):172-181.
    View in: PubMed
    Score: 0.006
  58. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999 Jun 29; 99(25):3224-6.
    View in: PubMed
    Score: 0.006
  59. Acute Kidney Injury With Ventricular Assist Device Placement: National Estimates of Trends and Outcomes. Am J Kidney Dis. 2019 11; 74(5):650-658.
    View in: PubMed
    Score: 0.006
  60. Understanding by General Providers of the Echocardiogram Report. Am J Cardiol. 2019 07 15; 124(2):296-302.
    View in: PubMed
    Score: 0.006
  61. Association of Body Mass Index With Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2019 01; 12(1):e004817.
    View in: PubMed
    Score: 0.006
  62. Implantable Ventricular Assist Device Use and Outcomes in People With End-Stage Renal Disease. J Am Heart Assoc. 2018 07 06; 7(14).
    View in: PubMed
    Score: 0.005
  63. Effectiveness of NPs and PAs in managing diabetes and cardiovascular disease. JAAPA. 2018 Jul; 31(7):39-45.
    View in: PubMed
    Score: 0.005
  64. Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry. J Am Heart Assoc. 2018 06 09; 7(12).
    View in: PubMed
    Score: 0.005
  65. Trends in Left Ventricular Assist Device Implantation and Associated Mortality Among Patients With and Without ESRD. Am J Kidney Dis. 2018 10; 72(4):620-622.
    View in: PubMed
    Score: 0.005
  66. De Novo Heart Failure After Kidney Transplantation: Trends in Incidence and Outcomes. Am J Kidney Dis. 2018 08; 72(2):223-233.
    View in: PubMed
    Score: 0.005
  67. Short-Term Global Cardiovascular Disease Risk?Prediction in Older Adults. J Am Coll Cardiol. 2018 06 05; 71(22):2527-2536.
    View in: PubMed
    Score: 0.005
  68. Health Care Resource Utilization for Outpatient Cardiovascular Disease and Diabetes Care Delivery Among Advanced Practice Providers and Physician Providers in Primary Care. Popul Health Manag. 2018 06; 21(3):209-216.
    View in: PubMed
    Score: 0.005
  69. Comparison of Frequency of Cardiovascular Events and Mortality in Patients With Heart Failure Using Versus Not Using Cocaine. Am J Cardiol. 2017 06 15; 119(12):2030-2034.
    View in: PubMed
    Score: 0.005
  70. Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail. 2016 08; 9(8).
    View in: PubMed
    Score: 0.005
  71. Risk Factor Optimization and Guideline-Directed Medical Therapy in US Veterans With Peripheral Arterial and Ischemic Cerebrovascular Disease Compared to Veterans With Coronary Heart Disease. Am J Cardiol. 2016 Oct 15; 118(8):1144-1149.
    View in: PubMed
    Score: 0.005
  72. Guideline-Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. Clin Cardiol. 2016 Mar; 39(3):145-9.
    View in: PubMed
    Score: 0.005
  73. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2016 Feb 16; 133(7):631-8.
    View in: PubMed
    Score: 0.005
  74. Provider Type and Quality of Outpatient Cardiovascular Disease Care: Insights From the NCDR PINNACLE Registry. J Am Coll Cardiol. 2015 Oct 20; 66(16):1803-1812.
    View in: PubMed
    Score: 0.004
  75. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. Circ Heart Fail. 2015 Nov; 8(6):1052-8.
    View in: PubMed
    Score: 0.004
  76. Response to Letter Regarding Article, ?Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction?. Circ Heart Fail. 2015 Jul; 8(4):840.
    View in: PubMed
    Score: 0.004
  77. Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 2015 May 19; 131(20):1763-71.
    View in: PubMed
    Score: 0.004
  78. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail. 2015 May; 8(3):533-41.
    View in: PubMed
    Score: 0.004
  79. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry. J Am Coll Cardiol. 2015 Jan 20; 65(2):111-21.
    View in: PubMed
    Score: 0.004
  80. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. Eur Heart J. 2015 Apr 14; 36(15):939-45.
    View in: PubMed
    Score: 0.004
  81. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol. 2015 Jan 01; 115(1):21-6.
    View in: PubMed
    Score: 0.004
  82. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail. 2014 Aug; 2(4):412-21.
    View in: PubMed
    Score: 0.004
  83. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA. 2013 Dec 18; 310(23):2533-43.
    View in: PubMed
    Score: 0.004
  84. Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. Circ Heart Fail. 2014 Jan; 7(1):123-30.
    View in: PubMed
    Score: 0.004
  85. Association between preoperative diuretic use and in-hospital outcomes after cardiac surgery. Cardiovasc Ther. 2013 Oct; 31(5):291-7.
    View in: PubMed
    Score: 0.004
  86. Troponin T and N-terminal pro-B-type natriuretic peptide: a biomarker approach to predict heart failure risk--the atherosclerosis risk in communities study. Clin Chem. 2013 Dec; 59(12):1802-10.
    View in: PubMed
    Score: 0.004
  87. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013 Mar 27; 309(12):1268-77.
    View in: PubMed
    Score: 0.004
  88. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012 Dec 13; 367(24):2296-304.
    View in: PubMed
    Score: 0.004
  89. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J. 2012 Nov; 164(5):763-770.e3.
    View in: PubMed
    Score: 0.004
  90. Echocardiographic changes during treatment of acute decompensated heart failure: insights from the ESCAPE trial. J Card Fail. 2012 Oct; 18(10):792-8.
    View in: PubMed
    Score: 0.004
  91. Worsening renal function is not associated with response to treatment in acute heart failure. Int J Cardiol. 2013 Sep 01; 167(5):1912-7.
    View in: PubMed
    Score: 0.004
  92. Classification of heart failure in the atherosclerosis risk in communities (ARIC) study: a comparison of diagnostic criteria. Circ Heart Fail. 2012 Mar 01; 5(2):152-9.
    View in: PubMed
    Score: 0.003
  93. New insights into mechanisms of action of carvedilol treatment in chronic heart failure patients--a matter of time for contractility. J Card Fail. 2012 Mar; 18(3):183-93.
    View in: PubMed
    Score: 0.003
  94. Recurrent low-level troponin I elevation is a worse prognostic indicator than occasional injury pattern in patients hospitalized with heart failure. Int J Cardiol. 2013 Jun 20; 166(2):394-8.
    View in: PubMed
    Score: 0.003
  95. Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure. Pharmacoepidemiol Drug Saf. 2012 Mar; 21(3):233-40.
    View in: PubMed
    Score: 0.003
  96. New predictive models of heart failure mortality using time-series measurements and ensemble models. Circ Heart Fail. 2011 Jul; 4(4):456-62.
    View in: PubMed
    Score: 0.003
  97. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 03; 364(9):797-805.
    View in: PubMed
    Score: 0.003
  98. Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: a complex relationship. Am Heart J. 2011 Mar; 161(3):567-73.
    View in: PubMed
    Score: 0.003
  99. The potentially modifiable burden of incident heart failure due to obesity: the atherosclerosis risk in communities study. Am J Epidemiol. 2010 Oct 01; 172(7):781-9.
    View in: PubMed
    Score: 0.003
  100. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vasc Health Risk Manag. 2010 Aug 09; 6:449-55.
    View in: PubMed
    Score: 0.003
  101. Digoxin treatment in heart failure--unveiling risk by cluster analysis of DIG data. Int J Cardiol. 2011 Aug 04; 150(3):264-9.
    View in: PubMed
    Score: 0.003
  102. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010 Feb 01; 105(3):373-7.
    View in: PubMed
    Score: 0.003
  103. Impact of alpha 1-adrenergic antagonist use for benign prostatic hypertrophy on outcomes in patients with heart failure. Am J Cardiol. 2009 Jul 15; 104(2):270-5.
    View in: PubMed
    Score: 0.003
  104. Reduction in BNP levels with treatment of decompensated heart failure and future clinical events. J Card Fail. 2009 May; 15(4):293-9.
    View in: PubMed
    Score: 0.003
  105. The July effect and cardiac surgery: the effect of the beginning of the academic cycle on outcomes. Am J Surg. 2008 Nov; 196(5):720-5.
    View in: PubMed
    Score: 0.003
  106. The metabolic syndrome and mortality in an ethnically diverse heart failure population. J Card Fail. 2008 Sep; 14(7):590-5.
    View in: PubMed
    Score: 0.003
  107. Circulating levels of tumor necrosis factor correlate with indexes of depressed heart rate variability: a study in patients with mild-to-moderate heart failure. Chest. 2003 Mar; 123(3):716-24.
    View in: PubMed
    Score: 0.002
  108. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002 Dec; 8(6):390-8.
    View in: PubMed
    Score: 0.002
  109. Quantification of the myocardial response to low-dose dobutamine using tissue Doppler echocardiographic measures of velocity and velocity gradient. Am J Cardiol. 1998 Mar 01; 81(5):615-23.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.